Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Cell Death Dis ; 4: e919, 2013 Nov 14.
Artículo en Inglés | MEDLINE | ID: mdl-24232095

RESUMEN

Genetic and epidemiologic evidence suggests that cellular energy homeostasis is critically associated with Parkinson's disease (PD) pathogenesis. Here we demonstrated that genetic deletion of Poly (ADP-ribose) polymerase 1 completely blocked 6-hydroxydopamine-induced dopaminergic neurodegeneration and related PD-like symptoms. Hyperactivation of PARP-1 depleted ATP pools in dopaminergic (DA) neurons, thereby activating AMP-activated protein kinase (AMPK). Further, blockade of AMPK activation by viral infection with dominant-negative AMPK strongly inhibited DA neuronal atrophy with moderate suppression of nuclear translocation of apoptosis-inhibiting factor (AIF), whereas overactivation of AMPK conversely strengthened the 6-OHDA-induced DA neuronal degeneration. Collectively, these results suggest that manipulation of PARP-1 and AMPK signaling is an effective therapeutic approach to prevent PD-related DA neurodegeneration.


Asunto(s)
Proteínas Quinasas Activadas por AMP/metabolismo , Dopamina/metabolismo , Neuronas/citología , Enfermedad de Parkinson/enzimología , Enfermedad de Parkinson/patología , Proteínas Quinasas Activadas por AMP/genética , Animales , Western Blotting , Cromatografía Líquida de Alta Presión , Modelos Animales de Enfermedad , Masculino , Espectrometría de Masas , Ratones , Ratones Noqueados , Neuronas/metabolismo , Enfermedad de Parkinson/metabolismo , Poli(ADP-Ribosa) Polimerasas/genética , Poli(ADP-Ribosa) Polimerasas/metabolismo
2.
Ann Acad Med Singap ; 30(4 Suppl): 41-9, 2001 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-11721278

RESUMEN

In October 1999, the Singapore Government introduced casemix-based funding to public hospitals. The casemix approach to health care funding is expected to yield significant benefits, including equity and rationality in financing health care, the use of comparative casemix data for quality improvement activities, and the provision of information that enables hospitals to understand their cost behaviour and reinforces the drive for more cost-efficient services. However, there is some concern about the "quicker and sicker" syndrome (that is, the rapid discharge of patients with little regard for the quality of outcome). As it is likely that consequences of premature discharges will be reflected in the readmission data, an analysis of possible systematic patterns in readmission data can provide useful insight into the "quicker and sicker" syndrome. This paper explores potential data mining applications in the context of casemix by using readmission data as an illustration. In particular, it illustrates how data mining can be used to better understand readmission data and to detect systematic patterns, if any. From a technical perspective, data mining (which is capable of analysing complex non-linear and interaction relationships) supplements and complements traditional statistical methods in data analysis. From an applications perspective, data mining provides the technology and methodology to analyse mass volume of data to detect hidden patterns in data. Using readmission data as an illustrative data mining application, this paper explores potential data mining applications in the general casemix context.


Asunto(s)
Técnicas de Apoyo para la Decisión , Grupos Diagnósticos Relacionados/estadística & datos numéricos , Hospitalización/estadística & datos numéricos , Análisis por Conglomerados , Interpretación Estadística de Datos , Episodio de Atención , Humanos , Redes Neurales de la Computación , Readmisión del Paciente/estadística & datos numéricos
3.
J Korean Med Sci ; 16(5): 598-602, 2001 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-11641529

RESUMEN

This study was aimed to evaluate renal dysfunction during three weeks after the burn injuries in 12 patients admitted to the Hallym University Hankang Medical Center with flame burn injuries (total body surface area, 20-40%). Parameters assessed included 24-hr urine volume, blood urea nitrogen, serum creatinine, creatinine clearance, total urinary protein, urinary microalbumin, 24-hr urinary N-acetyl-beta-D-glucosaminidase (NAG) activity, and urinary malondialdehyde (MDA). Statistical analysis was performed using repeated measures ANOVA test. The 24-hr urine volume, creatinine clearance, and urinary protein significantly increased on day 3 post-burn and fell thereafter. The urine microalbumin excretion showed two peak levels on day 0 post-burn and day 3. The 24-hr urinary NAG activity significantly increased to its maximal level on day 7 post-burn and gradually fell thereafter. The urinary MDA progressively increased during 3 weeks after the burn injury. Despite recovery of general renal function through an intensive care of burn injury, renal tubular damage and lipid peroxidation of the renal tissue suggested to persist during three weeks after the burn. Therefore, a close monitoring and intensive management of renal dysfunction is necessary to prevent burn-induced acute renal failure as well as to lower mortality in patients with major burns.


Asunto(s)
Acetilglucosaminidasa/orina , Quemaduras/complicaciones , Enfermedades Renales/diagnóstico , Malondialdehído/orina , Lesión Renal Aguda/diagnóstico , Adulto , Anciano , Albuminuria/etiología , Biomarcadores , Femenino , Humanos , Enfermedades Renales/orina , Peroxidación de Lípido , Masculino , Persona de Mediana Edad
4.
J Auton Pharmacol ; 21(5-6): 249-54, 2001.
Artículo en Inglés | MEDLINE | ID: mdl-12123470

RESUMEN

1 Injection of N(6)-cyclohexyladenosine (CHA; 1, 5 and 10 nmol), an adenosine A1 receptor agonist, into the posterior hypothalamus of rats produced a dose-dependent decrease in blood pressure (BP) and heart rate (HR). 2 Pretreatment with 8-cyclopentyl-1,3-dimethylxanthine (CPDX; 50 nmol), an adenosine A1 receptor antagonist, blocked the depressor and bradycardic effects of CHA (10 nmol). 3 Pretreatment with 8-bromo-cyclic adenosine monophosphate (AMP) (10 nmol), a cAMP analogue, attenuated the depressor and bradycardic effect of CHA (10 nmol); 8-bromo-cyclic guanosine monophosphate (GMP) (10 nmol), a cGMP analogue, did not modify those effects of CHA. 4 In addition, pretreatment with 5-aminovaleric acid (25 nmol), a gamma-aminobutyric acid (GABA)(B) receptor antagonist, attenuated the depressor and bradycardic effects of CHA (10 nmol). 5 These results suggest that adenosine A1 receptors in the posterior hypothalamus have an inhibitory role in the central cardiovascular regulation and that these vasodepressive and bradycardic actions are modified by raised cAMP and by GABA(B) receptor inhibition.


Asunto(s)
Adenosina/análogos & derivados , Presión Sanguínea/efectos de los fármacos , AMP Cíclico/fisiología , Frecuencia Cardíaca/efectos de los fármacos , Hipotálamo Posterior/fisiología , Receptores de GABA-B/fisiología , Receptores Purinérgicos P1/fisiología , Teofilina/análogos & derivados , Adenosina/farmacología , Anestesia , Animales , Antagonistas de Receptores de GABA-B , Masculino , Ratas , Ratas Sprague-Dawley , Teofilina/farmacología
5.
Biochem Biophys Res Commun ; 278(2): 426-31, 2000 Nov 19.
Artículo en Inglés | MEDLINE | ID: mdl-11097853

RESUMEN

Our previous study suggested that the region encompassing residues 220-240 on G(alpha16) is important in coupling with C5a receptor (Lee et al. (1995) Mol. Pharmacol. 47, 218-223). When aligned sequences are compared in the residue 220-240 segment of G(alpha16), there is a block of eight amino acids extending from residue 227 to residue 234 (227-Ile-Ala-Leu-Ile-Tyr-Leu-Ala-Ser-234) in G(alpha16) that is replaced by a heterologous block extending from amino acid residue 224 to residue 231 (224-Thr-Ser-Ile-Met-Phe-Leu-Val-Ala-231) in G(alpha11). In order to identify the specific amino acid residue necessary for coupling to C5a receptor within the extension of eight amino acids in G(alpha16), a series of chimeric G(alpha11)/G(alpha16) cDNA constructs and mutant G(alpha16) cDNAs were expressed. Then the ability of chimeras and mutant proteins to mediate C5a-induced release of inositol phosphate in transfected Cos-7 cells was tested. The results show that single amino acid Ala(228) is responsible for conferring about 40-50% of the activity of G(alpha16) induced by C5a receptor stimulation.


Asunto(s)
Alanina/metabolismo , Antígenos CD/metabolismo , Proteínas de Unión al GTP/metabolismo , Fosfatos de Inositol/metabolismo , Receptores de Complemento/metabolismo , Secuencia de Aminoácidos , Animales , Secuencia de Bases , Células COS , Cartilla de ADN , Proteínas de Unión al GTP/química , Hidrólisis , Receptor de Anafilatoxina C5a
6.
Neurosci Lett ; 296(2-3): 153-7, 2000 Dec 22.
Artículo en Inglés | MEDLINE | ID: mdl-11109004

RESUMEN

Cardiovascular inhibitory effects induced by intrathecal (i.t.) administration of adenosine A(1) receptor agonist and its modulation by gamma-aminobutyric acid(B) (GABA(B)) receptor was suggested by our previous report. In this experiment, we examined the mediation of cardiovascular effects of GABA(B) receptor stimulation by adenosine A(1) and A(2) in the spinal cord. I.t. administration of GABA(B) receptor agonist, baclofen (30, 60 and 100 nmol) produced a dose dependent decrease of blood pressure and heart rate. Pretreatment with adenosine A(1) receptor antagonist, 8-cyclopentyl-1,3-dimethylxanthine (50 nmol), attenuated the depressor and bradycardiac effects of baclofen (100 nmol), but not with adenosine A(2) receptor antagonist, 3, 7-dimethyl-1-propargylxanthine (25 nmol). These results suggest that GABA(B) receptors in the spinal cord play an inhibitory role in the central cardiovascular regulation and that the depressor and bradycardiac actions are mediated by adenosine A(1) receptors.


Asunto(s)
Fenómenos Fisiológicos Cardiovasculares/efectos de los fármacos , Neuronas/efectos de los fármacos , Receptores de GABA-B/efectos de los fármacos , Receptores Purinérgicos P1/efectos de los fármacos , Médula Espinal/efectos de los fármacos , Teobromina/análogos & derivados , Teofilina/análogos & derivados , Adenosina/metabolismo , Aminoácidos Neutros/farmacología , Animales , Baclofeno/farmacología , Presión Sanguínea/efectos de los fármacos , Presión Sanguínea/fisiología , Relación Dosis-Respuesta a Droga , Frecuencia Cardíaca/efectos de los fármacos , Frecuencia Cardíaca/fisiología , Masculino , Neuronas/citología , Neuronas/metabolismo , Ratas , Ratas Sprague-Dawley , Receptores de GABA-B/metabolismo , Receptores Purinérgicos P1/metabolismo , Médula Espinal/citología , Médula Espinal/metabolismo , Sistema Nervioso Simpático/citología , Sistema Nervioso Simpático/efectos de los fármacos , Sistema Nervioso Simpático/metabolismo , Teobromina/farmacología , Teofilina/farmacología , Ácido gamma-Aminobutírico/metabolismo
7.
Neurosci Lett ; 293(1): 45-8, 2000 Oct 20.
Artículo en Inglés | MEDLINE | ID: mdl-11065134

RESUMEN

This study was performed to investigate the influence of spinal adenosine A2 receptors on the central regulation of blood pressure (BP) and heart rate (HR), and to define whether its mechanism is mediated by adenylate cyclase or guanylate cyclase. Intrathecal (i.t.) administration of drugs at the thoracic level were performed in anesthetized, artificially ventilated male Sprague-Dawley rats. Injection (i.t.) of adenosine A2 receptor agonist, 5'-(N-cyclopropyl)-carboxamidoadenosine (CPCA; 1, 2 and 3 nmol) produced a dose dependent decrease of BP and HR. Pretreatment with adenylate cyclase inhibitor, MDL-12,330, attenuated the depressor and bradycardiac effects of CPCA (2 nmol), but not with guanylate cyclase inhibitor, LY-83,583. These results suggest that adenosine A2 receptor in the spinal cord plays an inhibitory role in the central cardiovascular regulation and that the depressor and bradycardiac actions are mediated by adenylate cyclase.


Asunto(s)
Adenosina/análogos & derivados , Adenilil Ciclasas/farmacología , Adenilil Ciclasas/fisiología , Sistema Cardiovascular/efectos de los fármacos , Agonistas del Receptor Purinérgico P1 , Médula Espinal/enzimología , Adenosina/farmacología , Aminoquinolinas/farmacología , Animales , Presión Sanguínea/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Inhibidores Enzimáticos/farmacología , Guanilato Ciclasa/antagonistas & inhibidores , Frecuencia Cardíaca/efectos de los fármacos , Iminas/farmacología , Inyecciones Espinales , Ratas , Tórax
8.
J Auton Pharmacol ; 19(6): 347-52, 1999 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-10961740

RESUMEN

1. Intrathecal (i.t.) injection of baclofen (30, 60 and 100 nmol), a GABA(B) receptor agonist, produced a dose-dependent decrease in blood pressure (BP) and heart rate (HR). 2. Pretreatment with 5-aminovaleric acid (50 nmol), a GABA(B) receptor antagonist, blocked the depressor and bradycardic effects of baclofen (100 nmol). 3. Pretreatment with 8-bromo-cAMP (10 nmol), a cAMP analogue, attenuated the depressor and bradycardic effects of baclofen (100 nmol), but not with 8-bromo-cGMP (10 nmol), a cGMP analogue. 4. In addition, pretreatment with glipizide (20 nmol), an ATP-sensitive K+ channel (K(ATP)) blocker, attenuated the depressor and bradycardic effects of baclofen (100 nmol). These results suggest that GABA(B) receptors in the spinal cord have an inhibitory role in the central cardiovascular regulation and that these depressive and bradycardic actions are modified by cAMP and by K(ATP) channel blockade.


Asunto(s)
Presión Sanguínea/fisiología , Frecuencia Cardíaca/fisiología , Canales de Potasio/fisiología , Receptores de GABA-B/fisiología , Médula Espinal/fisiología , Anestesia General , Animales , Baclofeno/farmacología , Presión Sanguínea/efectos de los fármacos , AMP Cíclico/fisiología , GMP Cíclico/fisiología , Relación Dosis-Respuesta a Droga , Agonistas del GABA/farmacología , Frecuencia Cardíaca/efectos de los fármacos , Canales de Potasio/efectos de los fármacos , Ratas , Ratas Sprague-Dawley , Receptores de GABA-B/efectos de los fármacos , Médula Espinal/efectos de los fármacos
9.
Neurosci Lett ; 243(1-3): 81-4, 1998 Feb 27.
Artículo en Inglés | MEDLINE | ID: mdl-9535118

RESUMEN

Cardiovascular inhibitory effects induced by intrathecal (i.t.) administration of adenosine A1 receptor agonist and its modulation by cyclic AMP was suggested by our previous report. In this experiment, we examined the mediation of cardiovascular effects of adenosine A1 receptor by gamma-aminobutyric acid receptors A and B [GABA(A) and GABA(B)] in the spinal cord. I.t. administration of 10 nmol of N6-cyclohexyladenosine (CHA), an adenosine A1 receptor agonist, and pretreatment with bicuculline (10 nmol, i.t), a GABA(A) receptor antagonist, and 5-aminovaleric acid (50 nmol, i.t.), a GABA(B) receptor antagonist, prior to injection of CHA were performed in anesthetized, artificially ventilated Sprague-Dawley rats. I.t. injection of 50 nmol of 5-aminovaleric acid significantly attenuated the inhibitory cardiovascular effects of CHA but 10 nmol of bicuculline did not alter CHA-induced cardiovascular actions. It is suggested that cardiovascular responses of adenosine A1 receptor is mediated by GABA(B) receptor in the spinal cord.


Asunto(s)
Aminoácidos Neutros , Sistema Cardiovascular/inervación , Receptores de GABA-B/metabolismo , Receptores Purinérgicos P1/metabolismo , Médula Espinal/metabolismo , Adenosina/análogos & derivados , Adenosina/farmacología , Aminoácidos/farmacología , Animales , Bicuculina/farmacología , Presión Sanguínea/efectos de los fármacos , AMP Cíclico/metabolismo , Antagonistas del GABA/farmacología , Antagonistas de Receptores de GABA-A , Frecuencia Cardíaca/efectos de los fármacos , Masculino , Agonistas del Receptor Purinérgico P1 , Ratas , Ratas Sprague-Dawley , Receptores de GABA-A/metabolismo , Médula Espinal/química , Médula Espinal/efectos de los fármacos
10.
Arch Pharm Res ; 21(4): 423-8, 1998 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-9875470

RESUMEN

The ligand binding signals to a wide variety of seven transmembrane cell surface receptors are transduced into intracellular signals through heterotrimeric G-proteins. Recently, there have been reports which show diverse coupling patterns of ligand-activated receptors to the members of Gq family alpha subunits. In order to shed some light on these complex signal processing networks, interactions between G alpha q family of G protein and neurokinin-2 receptor as well as muscarinic M1 receptor, which are considered to be new therapeutic targets in asthma, were studied. Using washed membranes from Cos-7 cells co-transfected with different G alpha q and receptor cDNAs, the receptors were stimulated with various concentrations of carbachol and neurokinin A and the agonist-dependent release of [3H]inositol phosphates through phospholipase C beta-1 activation was measured. Differential coupling of G alpha q family of G-protein to muscarinic M1 receptor and neurokinin-2 receptor was observed. The neurokinin-2 receptor shows a ligand-mediated response in membranes co-transfected with G alpha q, G alpha 11 and G alpha 14 but not G alpha 16 and the ability of the muscarinic M1 receptor to activate phospholipase C through G alpha q/11 but not G alpha 14 and G alpha 16 was demonstrated. Clearly G alpha q/11 can couple M1 and neurokinin-2 receptor to activate phospholipase C. But, there are differences in the relative coupling of the G alpha 14 and G alpha 16 subunits to these receptors.


Asunto(s)
Proteínas de Unión al GTP/metabolismo , Receptores Muscarínicos/metabolismo , Receptores de Neuroquinina-2/metabolismo , Animales , Células COS , Carbacol/farmacología , Membrana Celular/metabolismo , Activación Enzimática , Proteínas de Unión al GTP/genética , Guanosina 5'-O-(3-Tiotrifosfato)/farmacología , Fosfatos de Inositol/biosíntesis , Isoenzimas/metabolismo , Datos de Secuencia Molecular , Fosfolipasa C beta , Unión Proteica , Receptor Muscarínico M1 , Receptores Muscarínicos/genética , Receptores de Neuroquinina-2/genética , Transfección , Fosfolipasas de Tipo C/metabolismo
11.
Neurosci Lett ; 219(3): 195-8, 1996 Nov 29.
Artículo en Inglés | MEDLINE | ID: mdl-8971813

RESUMEN

This study was performed to investigate the influence of the spinal adenosine A1 receptors on the central regulation of blood pressure (BP) and heart rate (HR), and to define whether its mechanism is mediated by cyclic AMP (cAMP) or cyclic GMP (cGMP). Intrathecal (i.t.) administration of drugs at the thoracic level were performed in anesthetized, artificially ventilated male Sprague-Dawley rats. Injection (i.t.) of adenosine A1 receptor agonist, N6-cyclohexyladenosine (CHA; 1, 5 and 10 nmol) produced dose dependent decrease of BP and HR. Pretreatment with a cAMP analogue, 8-bromo-cAMP, attenuated the depressor and bradycardiac effects of CHA (10 nmol), but not with cGMP analogue, 8-bromo-cGMP. These results suggest that adenosine A1 receptor in the spinal cord plays an inhibitory role in the central cardiovascular regulation and that this depressor and bradycardiac actions are mediated by cAMP.


Asunto(s)
Adenosina/análogos & derivados , Presión Sanguínea/efectos de los fármacos , AMP Cíclico/fisiología , Frecuencia Cardíaca/efectos de los fármacos , Agonistas del Receptor Purinérgico P1 , Médula Espinal/fisiología , 8-Bromo Monofosfato de Adenosina Cíclica/farmacología , Adenosina/farmacología , Animales , GMP Cíclico/análogos & derivados , GMP Cíclico/farmacología , Relación Dosis-Respuesta a Droga , Masculino , Ratas , Ratas Sprague-Dawley
12.
Neurosci Lett ; 203(1): 53-6, 1996 Jan 12.
Artículo en Inglés | MEDLINE | ID: mdl-8742045

RESUMEN

The present study was performed to investigate the role of spinal nitric oxide (NO) in the central regulation of blood pressure (BP). Experiments were carried out in anesthetized artificially ventilated male Wistar rats. Intrathecal (i.t.) administration of drugs was made at the thoracic spinal level. I.t. injection of a NO donor, sodium nitroprusside (SNP; 1, 5, and 15 nmol) increased BP dose-dependently. Intrathecal pretreatment of methylene blue (200 nmol) significantly attenuated the pressor response evoked by SNP (15 nmol, i.t.). I.t. administration of nitric oxide synthase inhibitor, NG-nitro-L-arginine methyl ester (100 and 1000 nmol), caused decreases in BP. These results suggest that NO plays a tonic excitatory role in the central regulation of BP in the rat spinal cord.


Asunto(s)
Presión Sanguínea/efectos de los fármacos , Frecuencia Cardíaca/efectos de los fármacos , Nitroprusiato/farmacología , Animales , Arginina/análogos & derivados , Arginina/farmacología , Relación Dosis-Respuesta a Droga , Inyecciones Espinales , Masculino , NG-Nitroarginina Metil Éster , Ratas , Ratas Wistar
13.
IEEE Trans Image Process ; 1(3): 269-80, 1992.
Artículo en Inglés | MEDLINE | ID: mdl-18296162

RESUMEN

A vector quantization scheme based on the classified vector quantization (CVQ) concept, called predictive classified vector quantization (PCVQ), is presented. Unlike CVQ where the classification information has to be transmitted, PCVQ predicts it, thus saving valuable bit rate. Two classifiers, one operating in the Hadamard domain and the other in the spatial domain, were designed and tested. The classification information was predicted in the spatial domain. The PCVQ schemes achieved bit rate reductions over the CVQ ranging from 20 to 32% for two commonly used color test images while maintaining the same acceptable image quality. Bit rates of 0.70-0.93 bits per pixel (bpp) were obtained depending on the image and PCVQ scheme used.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...